

Taxiarchis Kourelis

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1712376/taxiarchis-kourelis-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

289
papers

3,127
citations

29
h-index

46
g-index

321
ext. papers

4,147
ext. citations

4.4
avg, IF

5.1
L-index

#	Paper	IF	Citations
289	A simple additive staging system for newly diagnosed multiple myeloma.. <i>Blood Cancer Journal</i> , 2022 , 12, 21	7	4
288	Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab.. <i>Leukemia</i> , 2022 ,	10.7	2
287	Success of the autologous stem cell boost after autologous graft failure in multiple myeloma and AL amyloidosis.. <i>Bone Marrow Transplantation</i> , 2022 ,	4.4	
286	Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantation.. <i>Blood Cancer Journal</i> , 2022 , 12, 59	7	0
285	Acute seizures and status epilepticus in immune effector cell associated neurotoxicity syndrome (ICANS).. <i>Blood Cancer Journal</i> , 2022 , 12, 62	7	0
284	Lack of a caregiver is associated with shorter survival in myeloma patients undergoing autologous stem cell transplantation.. <i>Leukemia and Lymphoma</i> , 2022 , 1-6	1.9	0
283	Minimal Residual Disease Assessment in Multiple Myeloma Patients: Minimal Disease With Maximal Implications.. <i>Frontiers in Oncology</i> , 2021 , 11, 801851	5.3	1
282	Detection of Plasma Cell Disorders by Mass Spectrometry: A Comprehensive Review of 19,523 Cases. <i>Mayo Clinic Proceedings</i> , 2021 ,	6.4	2
281	Aging-associated immune system changes in multiple myeloma: The dark side of the moon. <i>Cancer Treatment and Research Communications</i> , 2021 , 29, 100494	2	1
280	"Real-Life" Data of the Efficacy and Safety of Belantamab Mafodotin in Relapsed Multiple Myeloma- the Mayo Clinic Experience. <i>Blood</i> , 2021 , 138, 1639-1639	2.2	2
279	Tracking Daratumumab Clearance Using Mass Spectrometric Approaches: Implications on M Protein Monitoring and Reusing Daratumumab. <i>Blood</i> , 2021 , 138, 2707-2707	2.2	
278	An Analysis of Virus Amplification and Antitumor Responses in T-Cell Lymphoma Patients Treated with Voyager-V1 (VSV-IFN β IS). <i>Blood</i> , 2021 , 138, 1333-1333	2.2	
277	Prognostic Role of IL-6 in POEMS Syndrome. <i>Blood</i> , 2021 , 138, 2700-2700	2.2	
276	Monoclonal Proteinuria Predicts Progression Risk in Asymptomatic Multiple Myeloma with a Free Light Chain Ratio \geq 100. <i>Blood</i> , 2021 , 138, 1617-1617	2.2	
275	Second Line Treatment Strategies in Multiple Myeloma: A Referral-Center Experience. <i>Blood</i> , 2021 , 138, 819-819	2.2	
274	Amyloidosis Composite Response Score Incorporating the Depth of Organ Response. <i>Blood</i> , 2021 , 138, 3805-3805	2.2	
273	Characterization of T-Cell Exhaustion in Rapid Progressing Multiple Myeloma Using Cross Center Scrna-Seq Study. <i>Blood</i> , 2021 , 138, 401-401	2.2	0

272	Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis. <i>Blood Cancer Journal</i> , 2021 , 11, 186	7	1
271	Response to COVID-19 Vaccination Post-CAR T Therapy in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma. <i>Blood</i> , 2021 , 138, 1750-1750	2.2	
270	Outcomes Following Biochemical or Clinical Progression in Patients with Multiple Myeloma. <i>Blood</i> , 2021 , 138, 3760-3760	2.2	0
269	Impact of Achieving an Early Complete Response in Multiple Myeloma and Predictors of Subsequent Outcome. <i>Blood</i> , 2021 , 138, 3773-3773	2.2	
268	Ocular Toxicity of Commercially Available Belantamab Mafodotin in Patients with Advanced Multiple Myeloma. <i>Blood</i> , 2021 , 138, 2711-2711	2.2	0
267	Histopathologic Characterization of Vexas Syndrome. <i>Blood</i> , 2021 , 138, 4656-4656	2.2	
266	Prognostic Factors for Early (<2 years) and Late (>5 years) Relapse in Multiple Myeloma- Pivotal Role of Cytogenetic Changes. <i>Blood</i> , 2021 , 138, 3761-3761	2.2	
265	Characteristics and risk factors for thrombosis in POEMS syndrome: A retrospective evaluation of 230 patients. <i>American Journal of Hematology</i> , 2021 ,	7.1	1
264	Outcomes of Triple Class (Proteasome Inhibitor, IMiDs and Monoclonal Antibody) Refractory Patients with Multiple Myeloma. <i>Blood</i> , 2021 , 138, 1632-1632	2.2	
263	Single-Cell RNA-Seq Analysis of CD138-Depleted Bone Marrow Samples Reveals Genetic Alterations and Disease Progression Correlate with Tumor and Bone Marrow Immune Microenvironment in the Mmrf Compass Study. <i>Blood</i> , 2021 , 138, 2691-2691	2.2	
262	Prognostic Impact of CD3 Count in Apheresis Collection in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant. <i>Blood</i> , 2021 , 138, 3774-3774	2.2	0
261	The Prognostic Utility of Serial MASS-FIX in Multiple Myeloma. <i>Blood</i> , 2021 , 138, 1619-1619	2.2	
260	Assessing the Prognostic Utility of the Mayo 2018 and IMWG 2020 Smoldering Multiple Myeloma Risk Stratification Scores When Applied Post Diagnosis. <i>Blood</i> , 2021 , 138, 543-543	2.2	
259	Factors Associated with Renal Impairment at Diagnosis in Multiple Myeloma with Survival Trends over Last Two Decades. <i>Blood</i> , 2021 , 138, 1630-1630	2.2	
258	Pilot Implementation of Remote Patient Monitoring Program for Outpatient Management of CAR-T Cell Therapy. <i>Blood</i> , 2021 , 138, 568-568	2.2	0
257	Mortality Trends in Multiple Myeloma after the Introduction of Novel Therapies in the United States. <i>Blood</i> , 2021 , 138, 119-119	2.2	
256	The Impact of the Central Carbon Energy Metabolism Transcriptome in the Pathogenesis and Outcomes of Multiple Myeloma. <i>Blood</i> , 2021 , 138, 2650-2650	2.2	
255	Single Cell Transcriptome Profile of Myeloma and Immune Cell Characteristics in Patients with Durable Response Post CART. <i>Blood</i> , 2021 , 138, 3838-3838	2.2	1

254	Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. <i>Leukemia</i> , 2021 ,	10.7	5
253	Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma. <i>Leukemia</i> , 2021 ,	10.7	1
252	Relapsed multiple myeloma demonstrates distinct patterns of immune microenvironment and malignant cell-mediated immunosuppression. <i>Blood Cancer Journal</i> , 2021 , 11, 45	7	5
251	Comments on: Chemotherapy-based approach is the preferred treatment for sporadic late-onset nemaline myopathy with a monoclonal protein. <i>International Journal of Cancer</i> , 2021 , 149, 741-742	7.5	0
250	Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent Therapy. <i>Mayo Clinic Proceedings</i> , 2021 , 96, 677-687	6.4	4
249	MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients. <i>Blood Cancer Journal</i> , 2021 , 11, 50	7	8
248	Microenvironment immune reconstitution patterns correlate with outcomes after autologous transplant in multiple myeloma. <i>Blood Advances</i> , 2021 , 5, 1797-1804	7.8	7
247	IGVL gene region usage correlates with distinct clinical presentation in IgM vs non-IgM light chain amyloidosis. <i>Blood Advances</i> , 2021 , 5, 2101-2105	7.8	5
246	Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design. <i>Leukemia</i> , 2021 , 35, 3604-3607	10.7	4
245	The Clinical Impact of Proteomics in Amyloid Typing. <i>Mayo Clinic Proceedings</i> , 2021 , 96, 1122-1127	6.4	2
244	Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update. <i>Mayo Clinic Proceedings</i> , 2021 , 96, 1546-1577	6.4	8
243	The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care Center. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021 , 21, 451-460.e2	2	2
242	Second Stem Cell Transplantation for Relapsed Refractory Light Chain (AL) Amyloidosis. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 589.e1-589.e6		2
241	Prognostic impact of posttransplant FDG PET/CT scan in multiple myeloma. <i>Blood Advances</i> , 2021 , 5, 2753-2759	7.8	0
240	Prognostic value of NT-ProBNP and troponin T in patients with light chain amyloidosis and kidney dysfunction undergoing autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2021 , 56, 274-277	4.4	0
239	A study from The Mayo Clinic evaluated long-term outcomes of kidney transplantation in patients with immunoglobulin light chain amyloidosis. <i>Kidney International</i> , 2021 , 99, 707-715	9.9	5
238	Outcomes of multiple myeloma patients with del 17p undergoing autologous stem cell transplantation. <i>American Journal of Hematology</i> , 2021 , 96, E35-E38	7.1	0
237	Characterization and prognostic implication of delayed complete response in AL amyloidosis. <i>European Journal of Haematology</i> , 2021 , 106, 354-361	3.8	3

236	Use of beta blockers is associated with survival outcome of multiple myeloma patients treated with pomalidomide. <i>European Journal of Haematology</i> , 2021 , 106, 433-436	3.8	0
235	Autologous stem cell transplantation for multiple myeloma patients aged ≥ 75 treated with novel agents. <i>Bone Marrow Transplantation</i> , 2021 , 56, 1144-1150	4.4	5
234	Implications of detecting serum monoclonal protein by MASS-fix following stem cell transplantation in multiple myeloma. <i>British Journal of Haematology</i> , 2021 , 193, 380-385	4.5	9
233	Non-cardiac biopsy sites with high frequency of transthyretin amyloidosis. <i>ESC Heart Failure</i> , 2021 , 8, 750-755	3.7	3
232	Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (VRd) as first-line therapy in multiple myeloma. <i>American Journal of Hematology</i> , 2021 , 96, 330-337	7.1	3
231	Depth of response prior to autologous stem cell transplantation predicts survival in light chain amyloidosis. <i>Bone Marrow Transplantation</i> , 2021 , 56, 928-935	4.4	2
230	Prognostic Implications of Rising Serum Monoclonal Protein and Free Light Chains after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 309.e1-309.e5		
229	Retroperitoneal involvement with light chain amyloidosis- case series and literature review. <i>Leukemia and Lymphoma</i> , 2021 , 62, 316-322	1.9	1
228	Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patients. <i>Leukemia</i> , 2021 , 35, 1428-1437	10.7	4
227	Prognostic restaging after treatment initiation in patients with AL amyloidosis. <i>Blood Advances</i> , 2021 , 5, 1029-1036	7.8	3
226	Coagulation Abnormalities in Light Chain Amyloidosis. <i>Mayo Clinic Proceedings</i> , 2021 , 96, 377-387	6.4	3
225	Treatment and outcome of newly diagnosed multiple myeloma patients > 75 years old: a retrospective analysis. <i>Leukemia and Lymphoma</i> , 2021 , 62, 3011-3018	1.9	0
224	Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials. <i>American Journal of Hematology</i> , 2021 , 96, 1131-1136	7.1	6
223	MALDI-TOF mass spectrometry can distinguish immunofixation bands of the same isotype as monoclonal or biclonal proteins. <i>Clinical Biochemistry</i> , 2021 , 97, 67-73	3.5	1
222	The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM). <i>Blood Cancer Journal</i> , 2021 , 11, 158	7	1
221	The Efficacy and Safety of Chemotherapy-Based Stem Cell Mobilization in Multiple Myeloma Patients Who Are Poor Responders to Induction: The Mayo Clinic Experience. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 770.e1-770.e7		0
220	Clinical Heterogeneity of the VEXAS Syndrome: A Case Series. <i>Mayo Clinic Proceedings</i> , 2021 , 96, 2653-2659	6.5	7
219	Amyloid light-chain deposition in a schwannoma. <i>Interdisciplinary Neurosurgery: Advanced Techniques and Case Management</i> , 2021 , 26, 101301	0.5	

218	Comparison of the current renal staging, progression and response criteria to predict renal survival in AL amyloidosis using a Mayo cohort. <i>American Journal of Hematology</i> , 2021 , 96, 446-454	7.1	3
217	"Real-life" data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma-the Mayo Clinic experience. <i>Blood Cancer Journal</i> , 2021 , 11, 196	7	3
216	Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients. <i>Blood Cancer Journal</i> , 2020 , 10, 124	7	1
215	Differences in engraftment with day-1 compared with day-2 melphalan prior to stem cell infusion in myeloma patients receiving autologous stem cell transplant. <i>Bone Marrow Transplantation</i> , 2020 , 55, 2132-2137	4.4	5
214	Prognostic Role of Beta-2 Microglobulin in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 1402-1405	4.7	2
213	The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?. <i>Blood Cancer Journal</i> , 2020 , 10, 52	7	4
212	Venetoclax for the treatment of translocation (11;14) AL amyloidosis. <i>Blood Cancer Journal</i> , 2020 , 10, 55	7	22
211	Monoclonal Gammopathy of Undetermined Significance: Indications for Prediagnostic Testing, Subsequent Diagnoses, and Follow-up Practice at Mayo Clinic. <i>Mayo Clinic Proceedings</i> , 2020 , 95, 944-954	6.4	0
210	Bortezomib-based consolidation or maintenance therapy for multiple myeloma: a meta-analysis. <i>Blood Cancer Journal</i> , 2020 , 10, 33	7	12
209	Utilizing multiparametric flow cytometry in the diagnosis of patients with primary plasma cell leukemia. <i>American Journal of Hematology</i> , 2020 , 95, 637-642	7.1	6
208	N-glycosylation of monoclonal light chains on routine MASS-FIX testing is a risk factor for MGUS progression. <i>Leukemia</i> , 2020 , 34, 2749-2753	10.7	17
207	Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis. <i>Blood Cancer Journal</i> , 2020 , 10, 20	7	18
206	Mass cytometry identifies expansion of double positive and exhausted T cell subsets in the tumour microenvironment of patients with POEMS syndrome. <i>British Journal of Haematology</i> , 2020 , 190, 79-83	4.5	0
205	Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis. <i>Blood Cancer Journal</i> , 2020 , 10, 4	7	12
204	Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis. <i>American Journal of Hematology</i> , 2020 , 95, 497-502	7.1	27
203	Glycosylation of immunoglobulin light chains is highly prevalent in cold agglutinin disease. <i>American Journal of Hematology</i> , 2020 , 95, E222-E225	7.1	11
202	Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020 , 20, 596-601	2	3
201	Integrated Cytof, Scrna-Seq and Cite-Seq Analysis of Bone Marrow Immune Microenvironment in the Mmrf Compass Study. <i>Blood</i> , 2020 , 136, 28-29	2.2	1

200	Comparison of Conventional Xrays with CT Based Approaches for Detection of Lytic Lesions in Multiple Myeloma. <i>Blood</i> , 2020 , 136, 27-28	2.2	
199	Architecture of Sample Preparation and Data Governance of Immuno-Genomic Data Collected from Bone Marrow and Peripheral Blood Samples Obtained from Multiple Myeloma Patients. <i>Blood</i> , 2020 , 136, 17-18	2.2	
198	A Cross Sectional Evaluation of Light Chain N-Glycosylation By MASS-FIX in Plasma Cell Disorders. <i>Blood</i> , 2020 , 136, 44-45	2.2	
197	Prognostic Impact of PET Findings Post-Transplant in Multiple Myeloma. <i>Blood</i> , 2020 , 136, 15-16	2.2	
196	Treatments and Outcomes of Newly Diagnosed Multiple Myeloma Patients > 75 Years Old: A Retrospective Analysis. <i>Blood</i> , 2020 , 136, 14-15	2.2	
195	Prognostic Restaging after Treatment Initiation in Patients with AL Amyloidosis. <i>Blood</i> , 2020 , 136, 6-7	2.2	
194	Outcomes of Multiple Myeloma Patients with Del 17p Undergoing Autologous Stem Cell Transplantation. <i>Blood</i> , 2020 , 136, 21-22	2.2	
193	A 3-Question Symptom Assessment Score Can Predict Outcomes in Newly Diagnosed Multiple Myeloma (MM). <i>Blood</i> , 2020 , 136, 21-22	2.2	
192	Autologous Stem Cell Transplantation for Multiple Myeloma Patients Aged ≥75 Treated with Novel Agents. <i>Blood</i> , 2020 , 136, 12-13	2.2	
191	Unmet Needs in AL Amyloidosis: Outcomes in the Modern Era Among the Highest Risk, Newly Diagnosed AL Amyloidosis Patients. <i>Blood</i> , 2020 , 136, 31-32	2.2	0
190	Retroperitoneal Involvement of Light Chain Amyloidosis-Case Series and Literature Review. <i>Blood</i> , 2020 , 136, 37-38	2.2	
189	Identification and Validation of CD138- Multiple Myeloma Immune and Tumor Subpopulations Using Cross Center Scrna-Seq Data. <i>Blood</i> , 2020 , 136, 15-15	2.2	
188	Decreased Cardiac Ejection Fraction Is Associated with Worse Survival in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. <i>Blood</i> , 2020 , 136, 41-42	2.2	
187	Describing the Cellular and Humoral Immune Tumor Microenvironment and Malignant Transcriptome across the Multiple Myeloma Disease Spectrum. <i>Blood</i> , 2020 , 136, 39-40	2.2	2
186	A Phase I Dose Escalation Study of PT-112 in Patients with Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2020 , 136, 9-10	2.2	1
185	Characterization of Plasma and Immune Cells Molecular Landscape That Play a Role in Rapid Progression of Multiple Myeloma Using Cross Center Scrna-Seq Study. <i>Blood</i> , 2020 , 136, 6-8	2.2	
184	Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone for Treatment of Previously Untreated Light Chain Amyloidosis. <i>Blood</i> , 2020 , 136, 52-53	2.2	2
183	MASS-FIX for the Diagnosis of Plasma Cell Disorders: A Single Institution Experience of 4118 Patients. <i>Blood</i> , 2020 , 136, 48-49	2.2	0

182	Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2020 , 136, 36-37	2.2	3
181	Continued Improvement in Survival of Patients with Newly Diagnosed Multiple Myeloma (MM). <i>Blood</i> , 2020 , 136, 30-31	2.2	2
180	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). <i>Blood</i> , 2020 , 136, 7-8	2.2	1
179	Sequential Comparison of Conventional Serum Immunofixation (IFE) to Mass Spectrometry-Based Assessment (MASS FIX) in Patients with Multiple Myeloma (MM). <i>Blood</i> , 2020 , 136, 12-13	2.2	2
178	Presence of a Measurable M-Spike before Autologous Stem Cell Transplantation Is Associated with Shorter Survival in Patients with Light Chain Amyloidosis. <i>Blood</i> , 2020 , 136, 22-23	2.2	1
177	Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma. <i>Blood Advances</i> , 2020 , 4, 2236-2244	7.8	7
176	Delayed neutrophil engraftment in patients receiving Daratumumab as part of their first induction regimen for multiple myeloma. <i>American Journal of Hematology</i> , 2020 , 95, E8-E10	7.1	5
175	Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients. <i>American Journal of Hematology</i> , 2020 , 95, 4-9	7.1	6
174	Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020 , 20, 53-56	2	5
173	Enhancing the R-ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells. <i>American Journal of Hematology</i> , 2020 , 95, 310-315	7.1	16
172	Implications and outcomes of MRD-negative multiple myeloma patients with immunofixation positivity. <i>American Journal of Hematology</i> , 2020 , 95, E60-E62	7.1	1
171	Impact of MYD88 mutation status on histological transformation of Waldenström Macroglobulinemia. <i>American Journal of Hematology</i> , 2020 , 95, 274-281	7.1	18
170	IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features. <i>Leukemia</i> , 2020 , 34, 1373-1382	10.7	22
169	Revisiting complete response in light chain amyloidosis. <i>Leukemia</i> , 2020 , 34, 1472-1475	10.7	10
168	Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis. <i>Leukemia</i> , 2020 , 34, 1135-1143	10.7	19
167	Colon perforation in multiple myeloma patients - A complication of high-dose steroid treatment. <i>Cancer Medicine</i> , 2020 , 9, 8895-8901	4.8	1
166	Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma. <i>Clinical Cancer Research</i> , 2020 , 26, 6581-6588	12.9	9
165	Predictors of short-term survival in Waldenström Macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2020 , 61, 2975-2979	1.9	1

164	Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratio. <i>American Journal of Hematology</i> , 2020 , 95, 1280-1287	7.1	10
163	A Proteomic Atlas of Cardiac Amyloid Plaques. <i>JACC: CardioOncology</i> , 2020 , 2, 632-643	3.8	11
162	Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities. <i>Blood Advances</i> , 2020 , 4, 3509-3519	7.8	27
161	Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response. <i>Blood Cancer Journal</i> , 2020 , 10, 82	7	17
160	Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2020 , 27, 13-16	2.7	21
159	Utility of serum free light chain ratio in response definition in patients with multiple myeloma. <i>Blood Advances</i> , 2020 , 4, 322-326	7.8	4
158	Mass cytometry dissects T cell heterogeneity in the immune tumor microenvironment of common dysproteinemias at diagnosis and after first line therapies. <i>Blood Cancer Journal</i> , 2019 , 9, 72	7	21
157	Comparative analysis of staging systems in AL amyloidosis. <i>Leukemia</i> , 2019 , 33, 811-814	10.7	15
156	Sporadic late-onset nemaline myopathy: Clinical spectrum, survival, and treatment outcomes. <i>Neurology</i> , 2019 , 93, e298-e305	6.5	28
155	The impact of re-induction prior to salvage autologous stem cell transplantation in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2019 , 54, 2039-2050	4.4	6
154	Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma. <i>Leukemia and Lymphoma</i> , 2019 , 60, 2960-2967	1.9	2
153	Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 1520-1525	4.7	6
152	Clinical features, laboratory characteristics and outcomes of patients with renal versus cardiac light chain amyloidosis. <i>British Journal of Haematology</i> , 2019 , 185, 701-707	4.5	10
151	Natural history of multiple myeloma with de novo del(17p). <i>Blood Cancer Journal</i> , 2019 , 9, 32	7	22
150	Autologous stem cell transplantation in patients with AL amyloidosis with impaired renal function. <i>Bone Marrow Transplantation</i> , 2019 , 54, 1775-1779	4.4	5
149	Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy. <i>American Journal of Hematology</i> , 2019 , 94, 751-756	7.1	6
148	Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis. <i>Leukemia</i> , 2019 , 33, 1268-1272	10.7	4
147	Assay to rapidly screen for immunoglobulin light chain glycosylation: a potential path to earlier AL diagnosis for a subset of patients. <i>Leukemia</i> , 2019 , 33, 254-257	10.7	40

146	Comparable outcomes using propylene glycol-free melphalan for autologous stem cell transplantation in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2019 , 54, 587-594	4.4	7
145	Plasma cell proliferative index post-transplant is a powerful predictor of prognosis in myeloma patients failing to achieve a complete response. <i>Bone Marrow Transplantation</i> , 2019 , 54, 442-447	4.4	5
144	Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. <i>Bone Marrow Transplantation</i> , 2019 , 54, 353-367	4.4	51
143	Ten-year survivors in AL amyloidosis: characteristics and treatment pattern. <i>British Journal of Haematology</i> , 2019 , 187, 588-594	4.5	26
142	Depth of organ response in AL amyloidosis is associated with improved survival: new proposed organ response criteria. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2019 , 26, 101-102	2.7	4
141	Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosis. <i>Blood Advances</i> , 2019 , 3, 1226-1229	7.8	3
140	Characteristics of long-term survivors with multiple myeloma: A National Cancer Data Base analysis. <i>Cancer</i> , 2019 , 125, 3574-3581	6.4	3
139	Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis. <i>American Journal of Hematology</i> , 2019 , 94, 1020-1026	7.1	25
138	Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosis. <i>American Journal of Hematology</i> , 2019 , 94, 1066-1071	7.1	9
137	Glycosylation of Immunoglobulin Light Chains Is Highly Prevalent in Cold Agglutinin Disease. <i>Blood</i> , 2019 , 134, 3510-3510	2.2	1
136	A Proteomic Atlas of Cardiac Amyloidosis. <i>Blood</i> , 2019 , 134, 1790-1790	2.2	1
135	Mortality of Patients with Multiple Myeloma after the Introduction of Novel Therapies in the United States. <i>Blood</i> , 2019 , 134, 72-72	2.2	1
134	Utilizing Multiparametric Flow Cytometry to Identify Patients with Primary Plasma Cell Leukemia at Diagnosis. <i>Blood</i> , 2019 , 134, 4334-4334	2.2	1
133	Peak Lymphocyte Count after CAR T Infusion Is a Clinically Accessible Test That Correlates with Clinical Response in Axicabtagene CiloleuceL Therapy for Lymphoma. <i>Blood</i> , 2019 , 134, 4106-4106	2.2	4
132	A Prospective Pilot Study of Ixazomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed or Relapsed/Refractory POEMS Syndrome. <i>Blood</i> , 2019 , 134, 1846-1846	2.2	2
131	Prognostic Implications of Serum Monoclonal Protein Positivity By Mass-Fix in Bone Marrow Minimal Residual Disease Negative (MRD-) Patients with Multiple Myeloma. <i>Blood</i> , 2019 , 134, 4386-4386 ^{2.2}	2.2	2
130	Phase 2 Trial of Daratumumab, Ixazomib, Lenalidomide and Modified Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2019 , 134, 864-864	2.2	12
129	Phase 2 Trial of LDE225 and Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Multiple Myeloma. <i>Blood</i> , 2019 , 134, 1905-1905	2.2	1

128	Prognostic Significance of Holter Monitor Findings in Patients With Light Chain Amyloidosis. <i>Mayo Clinic Proceedings</i> , 2019 , 94, 455-464	6.4	13
127	PS1397 OUTCOMES OF LONG-TERM SURVIVORS WITH ACTIVE MULTIPLE MYELOMA. <i>HemaSphere</i> , 2019 , 3, 641	0.3	
126	Delayed Neutrophil Engraftment in Patients Receiving Daratumumab As Part of Their First Induction Regimen for Multiple Myeloma. <i>Blood</i> , 2019 , 134, 4505-4505	2.2	
125	Hypovitaminosis D Is Prevalent in Patients with Renal AL Amyloidosis and Associated with Non-t(11;14). <i>Blood</i> , 2019 , 134, 5523-5523	2.2	
124	Metaphase Cytogenetics for Risk Stratification in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2019 , 134, 4396-4396	2.2	
123	Impact of sFLC Ratio on Outcome in Patients with MM: Validating the Utility of sFLC in Response Definition. <i>Blood</i> , 2019 , 134, 3080-3080	2.2	
122	Determinants of Clinical Trial Participation and Impact on Survival Outcomes Among Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2019 , 134, 5833-5833	2.2	
121	Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone in Relapsed Multiple Myeloma. <i>Blood</i> , 2019 , 134, 1904-1904	2.2	
120	Immunoglobulin Variable Gene Region (IGVL) Usage Correlates with Distinct Clinical Presentation in IgM Versus Non-IgM Light Chain Amyloidosis. <i>Blood</i> , 2019 , 134, 1770-1770	2.2	
119	Increased Mean Corpuscular Volume Is an Independent Predictor for Worse Overall Survival in Patients with Newly Diagnosed Light Chain Amyloidosis. <i>Blood</i> , 2019 , 134, 5532-5532	2.2	
118	Optimal Therapy for Relapsed AL Amyloidosis Post Autologous Stem Cell Transplant. <i>Blood</i> , 2019 , 134, 3171-3171	2.2	0
117	A Novel Approach to Risk Stratification in Multiple Myeloma Using ISS Stage and FISH. <i>Blood</i> , 2019 , 134, 1800-1800	2.2	1
116	The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2019 , 134, 2197-2197	2.2	
115	Use of Maintenance Therapy Post Autologous Stem Cell Transplantation Outside of Clinical Trial Setting for Multiple Myeloma: Single Institution Experience. <i>Blood</i> , 2019 , 134, 2013-2013	2.2	
114	Clinical Outcomes and Cytogenetic Features of Primary Plasma Cell Leukemia (pPCL) in the Era of Novel Agent Induction Therapy. <i>Blood</i> , 2019 , 134, 5490-5490	2.2	1
113	Monoclonal gammopathy plus positive amyloid biopsy does not always equal AL amyloidosis. <i>American Journal of Hematology</i> , 2019 , 94, E141-E143	7.1	13
112	Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma. <i>Leukemia</i> , 2019 , 33, 1273-1277	10.7	7
111	A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry-Verified Typing. <i>Mayo Clinic Proceedings</i> , 2019 , 94, 472-483	6.4	33

110	Impact of acquired del(17p) in multiple myeloma. <i>Blood Advances</i> , 2019 , 3, 1930-1938	7.8	20
109	Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma. <i>Blood Advances</i> , 2019 , 3, 744-750	7.8	15
108	Autologous Stem Cell Transplant for IgM-Associated Amyloid Light-Chain Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, e108-e111	4.7	11
107	Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2019 , 54, 1077-1081	4.4	3
106	Primary systemic amyloidosis in patients with Waldenström macroglobulinemia. <i>Leukemia</i> , 2019 , 33, 790-794	10.7	16
105	Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse. <i>Leukemia</i> , 2019 , 33, 730-738	10.7	11
104	Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio. <i>Leukemia</i> , 2019 , 33, 527-531	10.7	30
103	Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis. <i>Leukemia</i> , 2019 , 33, 531-536	10.7	60
102	Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2019 , 94, 306-311	7.1	9
101	Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis. <i>Leukemia</i> , 2018 , 32, 1421-1426	10.7	5
100	Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. <i>Leukemia</i> , 2018 , 32, 2240-2249	10.7	49
99	Plasma cell proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantation. <i>Haematologica</i> , 2018 , 103, 1229-1234	6.6	8
98	Time to plateau as a predictor of survival in newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2018 , 93, 889-894	7.1	8
97	Analysis of Clinical Factors and Outcomes Associated with Nonuse of Collected Peripheral Blood Stem Cells for Autologous Stem Cell Transplants in Transplant-Eligible Patients with Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 2127-2132	4.7	12
96	Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia. <i>Annals of Hematology</i> , 2018 , 97, 1417-1425	3	43
95	Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. <i>Leukemia</i> , 2018 , 32, 1811-1815	10.7	18
94	Safety Outcomes for Autologous Stem Cell Transplant in Multiple Myeloma. <i>Mayo Clinic Proceedings</i> , 2018 , 93, 56-58	6.4	12
93	Impact of duration of induction therapy on survival in newly diagnosed multiple myeloma patients undergoing upfront autologous stem cell transplantation. <i>British Journal of Haematology</i> , 2018 , 182, 71-77	4.5	9

92	Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma. <i>American Journal of Hematology</i> , 2018 , 93, 179-186	7.1	29
91	MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2018 , 93, 187-194	7.1	45
90	Pomalidomide-dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial. <i>Leukemia</i> , 2018 , 32, 719-728	10.7	12
89	Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation. <i>Leukemia</i> , 2018 , 32, 712-718	10.7	20
88	Autologous Stem Cell Transplant for Immunoglobulin Light Chain Amyloidosis Patients Aged 70 to 75. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 2157-2159	4.7	3
87	Serum free light chain measurements to reduce 24-h urine monitoring in patients with multiple myeloma with measurable urine monoclonal protein. <i>American Journal of Hematology</i> , 2018 , 93, 1207-1210	7.1	1
86	Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2018 , 93, 1384-1393	7.1	15
85	MASS-FIX may allow identification of patients at risk for light chain amyloidosis before the onset of symptoms. <i>American Journal of Hematology</i> , 2018 , 93, E368-E370	7.1	26
84	Kidney Involvement of Patients with Waldenström Macroglobulinemia and Other IgM-Producing B Cell Lymphoproliferative Disorders. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018 , 13, 1037-1046	6.9	32
83	Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. <i>Blood Cancer Journal</i> , 2018 , 8, 59	7	115
82	A universal solution for eliminating false positives in myeloma due to therapeutic monoclonal antibody interference. <i>Blood</i> , 2018 , 132, 670-672	2.2	33
81	Mass Cytometry Identifies Immunomic Shifts in the Bone Marrow Microenvironment of Multiple Myeloma and Light Chain Amyloidosis after Standard of Care First Line Therapies. <i>Blood</i> , 2018 , 132, 1879-1879 ¹	2.2	1
80	Phase 2 Trial of Ixazomib, Lenalidomide, Dexamethasone and Daratumumab in Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2018 , 132, 304-304	2.2	8
79	IgM Associated Light Chain (AL) Amyloidosis: Delineating Disease Biology with Clinical, Genomic and Bone Marrow Morphological Features. <i>Blood</i> , 2018 , 132, 4460-4460	2.2	0
78	Long-Term Survivorship with Active Multiple Myeloma. <i>Blood</i> , 2018 , 132, 1912-1912	2.2	
77	Comparative Analysis of Staging Systems in AL Amyloidosis. <i>Blood</i> , 2018 , 132, 3228-3228	2.2	
76	Early Prediction of Treatment Response in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2018 , 132, 3159-3159		
75	Prognostic Significance of Early Immune Reconstitution in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2018 , 132, 3158-3158	2.2	

74	Impact of Acquired Del(17p) in Patients with Multiple Myeloma. <i>Blood</i> , 2018 , 132, 4449-4449	2.2	
73	Bortezomib, Lenalidomide and Dexamethasone (VRD) Followed By Autologous Stem Cell Transplant for Newly Diagnosed Multiple Myeloma; The Mayo Clinic Experience. <i>Blood</i> , 2018 , 132, 2147-2147	2.2	
72	Long-Term AL Amyloidosis Survivors Among Non-Selected Referral Population. <i>Blood</i> , 2018 , 132, 3226-3226		
71	Salvage Autologous Stem Cell Transplantation in Multiple Myeloma: Investigating the Impact of Pre-Transplant Therapy. <i>Blood</i> , 2018 , 132, 4613-4613	2.2	
70	Expected Survival in Patients with Smoldering Multiple Myeloma and Multiple Myeloma. <i>Blood</i> , 2018 , 132, 4497-4497	2.2	
69	Mass Spectrometry to Measure Response in Immunoglobulin Light Chain Amyloidosis (AL). <i>Blood</i> , 2018 , 132, 4502-4502	2.2	
68	Development of Thrombocytopenia and Survival Outcomes in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2018 , 132, 1902-1902	2.2	
67	Prognostic Restaging at the Time of 2nd-Line Therapy in Patients with AL Amyloidosis. <i>Blood</i> , 2018 , 132, 5594-5594	2.2	
66	Optimizing Deep Response Assessment for AL Amyloidosis Using Involved Free Light Chain Level at End of Therapy. <i>Blood</i> , 2018 , 132, 3227-3227	2.2	
65	Plasma Cell Disorders in Patients with Age-Related Transthyretin (ATTRwt) Amyloidosis. <i>Blood</i> , 2018 , 132, 5610-5610	2.2	
64	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). <i>Blood</i> , 2018 , 132, 3268-3268	2.2	
63	Three Decades of Autologous Stem Cell Transplantation for Myeloma; Trends in Early Mortality and Survival. <i>Blood</i> , 2018 , 132, 3436-3436	2.2	
62	Impact of MYD88L265P mutation Status on Histological Transformation of Waldenstrom Macroglobulinemia. <i>Blood</i> , 2018 , 132, 2884-2884	2.2	1
61	Characterization of Exceptional Responders to Autologous Stem Cell Transplantation in Multiple Myeloma. <i>Blood</i> , 2018 , 132, 4615-4615	2.2	
60	Plasma Cell Proliferative Index Is an Independent Predictor of Progression in Smoldering Multiple Myeloma. <i>Blood</i> , 2018 , 132, 3160-3160	2.2	2
59	Patient-Reported Outcome Driven Case Management System for Hematology & Prospective Study. <i>Blood</i> , 2018 , 132, 719-719	2.2	
58	POEMS Syndrome: Diagnosis and Investigative Work-up. <i>Hematology/Oncology Clinics of North America</i> , 2018 , 32, 119-139	3.1	22
57	Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1323-1329	2.2	68

56	Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma. <i>Blood Cancer Journal</i> , 2018 , 8, 106	7	13
55	Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome. <i>Blood Cancer Journal</i> , 2018 , 8, 125	7	17
54	Utility and prognostic value of F-FDG positron emission tomography-computed tomography scans in patients with newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2018 , 93, 1518-1523 ¹	7.1	15
53	Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation. <i>Blood Advances</i> , 2018 , 2, 769-776	7.8	16
52	Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma. <i>Blood Advances</i> , 2018 , 2, 3149-3154	7.8	17
51	Prognostic Significance of Stringent Complete Response after Stem Cell Transplantation in Immunoglobulin Light Chain Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 2360-2364	4.7	13
50	Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition. <i>Annals of Medicine</i> , 2017 , 49, 545-551	1.5	27
49	Hematology patient reported symptom screen to assess quality of life for AL amyloidosis. <i>American Journal of Hematology</i> , 2017 , 92, 435-440	7.1	10
48	Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. <i>Blood</i> , 2017 , 129, 2111-2119	2.2	181
47	Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017 , 24, 40-41	2.7	3
46	The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma. <i>American Journal of Hematology</i> , 2017 , 92, E507-E512	7.1	3
45	Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy. <i>Mayo Clinic Proceedings</i> , 2017 , 92, 578-598	6.4	88
44	Clarifying immunoglobulin gene usage in systemic and localized immunoglobulin light-chain amyloidosis by mass spectrometry. <i>Blood</i> , 2017 , 129, 299-306	2.2	61
43	Immune-Mediated Autonomic Neuropathies following Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia. <i>Case Reports in Hematology</i> , 2017 , 2017, 6803804	0.7	
42	Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: The Mayo Clinic Experience. <i>Mayo Clinic Proceedings</i> , 2017 , 92, 908-917	6.4	43
41	Delineation of the timing of second-line therapy post-autologous stem cell transplant in patients with AL amyloidosis. <i>Blood</i> , 2017 , 130, 1578-1584	2.2	15
40	Elevation of serum lactate dehydrogenase in AL amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation. <i>British Journal of Haematology</i> , 2017 , 178, 888-895	4.5	14
39	Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenström macroglobulinemia. <i>British Journal of Haematology</i> , 2017 , 179, 98-105	4.5	12

38	Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials. <i>American Journal of Hematology</i> , 2017 , 92, 1146-1155	7.1	22
37	The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation. <i>Nephrology Dialysis Transplantation</i> , 2016 , 31, 1284-9	4.3	21
36	Efficacy of Carfilzomib (K), Pomalidomide (P), and Dexamethasone (d) in Heavily Pretreated Patients with Relapsed/ Refractory Multiple Myeloma (RRMM) in a Real World Setting. <i>Blood</i> , 2016 , 128, 3337-3337	2.2	5
35	Practice Patterns of Re-Initiation of Therapy at Time of Relapse or Progression Post- Autologous Stem Cell Transplant (ASCT) Among Patients with AL Amyloidosis. <i>Blood</i> , 2016 , 128, 3444-3444	2.2	1
34	The Prognostic Significance of Polyclonal Bone Marrow Plasma Cells in Patients with Actively Relapsing Multiple Myeloma. <i>Blood</i> , 2016 , 128, 1194-1194	2.2	
33	Ruxolitinib Remains Effective in Myelofibrosis after the Necessary Dose Reductions: Real-Life Data from a Multi-Center Observational Study. <i>Blood</i> , 2016 , 128, 5476-5476	2.2	
32	Outcome of Very Young (<40 years) Patients with Immunoglobulin Light Chain Amyloidosis (AL): A Case Control Study. <i>Blood</i> , 2016 , 128, 5576-5576	2.2	
31	Induction therapy pre-autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation. <i>American Journal of Hematology</i> , 2016 , 91, 984-8	7.1	37
30	Outcomes of patients with renal monoclonal immunoglobulin deposition disease. <i>American Journal of Hematology</i> , 2016 , 91, 1123-1128	7.1	52
29	Long-term outcome of patients with POEMS syndrome: An update of the Mayo Clinic experience. <i>American Journal of Hematology</i> , 2016 , 91, 585-9	7.1	40
28	Improving strategies for the diagnosis of cardiac amyloidosis. <i>Expert Review of Cardiovascular Therapy</i> , 2015 , 13, 945-61	2.5	3
27	Primary Myelodysplastic Syndromes: The Mayo Clinic Experience With 1000 Patients. <i>Mayo Clinic Proceedings</i> , 2015 , 90, 1623-38	6.4	10
26	Temozolomide induced bone marrow Suppression--A single institution outcome analysis and review of the literature. <i>American Journal of Hematology</i> , 2015 , 90, E183-4	7.1	11
25	Impact of Bone Marrow Plasmacytosis on Outcome in Patients with AL Amyloidosis Following Autologous Stem Cell Transplant. <i>Blood</i> , 2015 , 126, 3177-3177	2.2	3
24	Presentation and Outcomes of Localized Amyloidosis: The Mayo Clinic Experience. <i>Blood</i> , 2015 , 126, 4197-4197	2.2	5
23	Ruxolitinib Efficacy and Safety in Myelofibrosis: A Multicenter Observational Study. <i>Blood</i> , 2015 , 126, 5192-5192	2.2	
22	Long-term disease control in patients with newly diagnosed multiple myeloma after suspension of lenalidomide therapy. <i>American Journal of Hematology</i> , 2014 , 89, 302-5	7.1	2
21	Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias. <i>American Journal of Hematology</i> , 2014 , 89, 1051-4	7.1	25

20	Temozolomide Induced Bone Marrow Suppression- a Single Institution Outcome Analysis and Review of Literature. <i>Blood</i> , 2014 , 124, 1602-1602	2.2	2
19	Immunoglobulin Variable Region Family Usage and Outcomes of Patients with Systemic Light Chain Amyloidosis. <i>Blood</i> , 2014 , 124, 3402-3402	2.2	1
18	Myeloid malignancy presenting with a platelet storage pool disorder. <i>Leukemia and Lymphoma</i> , 2013 , 54, 1800-1	1.9	1
17	Evaluation of revised IPSS cytogenetic risk stratification and prognostic impact of monosomal karyotype in 783 patients with primary myelodysplastic syndromes. <i>American Journal of Hematology</i> , 2013 , 88, 690-3	7.1	29
16	Systemic amyloidosis associated with chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>American Journal of Hematology</i> , 2013 , 88, 375-8	7.1	28
15	Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4319-24	2.2	146
14	Long Term Response To Lenalidomide With and Without Continuous Therapy Among Patients With Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2013 , 122, 3209-3209	2.2	
13	Mastocytosis causing refractory hypotension after coronary angiography. <i>International Journal of Cardiology</i> , 2012 , 156, e43-4	3.2	1
12	Trisomy 8 as the sole cytogenetic abnormality in an adult patient with acute lymphoblastic leukemia. <i>Cancer Genetics</i> , 2012 , 205, 337-8	2.3	1
11	Metformin and cancer: new applications for an old drug. <i>Medical Oncology</i> , 2012 , 29, 1314-27	3.7	205
10	Amitriptyline and prochlorperazine inhibit proinflammatory mediator release from human mast cells: possible relevance to chronic fatigue syndrome. <i>Journal of Clinical Psychopharmacology</i> , 2011 , 31, 385-7	1.7	15
9	Treatment of synchronous mantle cell lymphoma and small lymphocytic lymphoma with bendamustine and rituximab. <i>Acta Haematologica</i> , 2011 , 126, 40-3	2.7	8
8	IL-32 is increased along with tryptase in lesional psoriatic skin and is up-regulated by substance P in human mast cells. <i>European Journal of Dermatology</i> , 2010 , 20, 865-7	0.8	31
7	Urocortin induces interleukin-6 release from rat cardiomyocytes through p38 MAP kinase, ERK and NF-kappaB activation. <i>Journal of Molecular Endocrinology</i> , 2009 , 42, 397-405	4.5	30
6	Tc2 response at the onset of COPD exacerbations. <i>Chest</i> , 2008 , 134, 483-488	5.3	37
5	Human mast cells stimulate activated T cells: implications for multiple sclerosis. <i>Annals of the New York Academy of Sciences</i> , 2008 , 1144, 74-82	6.5	36
4	Defective Peripheral Blood Endothelial Cell Progenitors in Patients with Scleroderma and Psoriatic Arthritis. <i>Blood</i> , 2008 , 112, 4724-4724	2.2	
3	Acquired inhibitors to coagulation factors in patients with gastrointestinal diseases. <i>European Journal of Gastroenterology and Hepatology</i> , 2002 , 14, 1383-7	2.2	29

- 2 Activated peripheral blood and endothelial cells in thalassemia patients. *Annals of Hematology*, **2001**, 80, 577-83 3 64
- 1 Reduced CD43 expression on the neutrophils of MDS patients correlates with an activated phenotype of these cells. *International Journal of Hematology*, **2001**, 73, 483-491 2-3 5